Cue Biopharma - Aset Bersih saben Siji Saham CUE

Cue Biopharma, Inc. (CUE) management is transparently developing the Immuno-STAT platform while requiring non-dilutive capital. The key book value metric reflects net asset dynamics, where 0.44 represents the current level of the metric. A strong team of immunologists is motivated by high bonuses, and medium-term catalysts are tied to clinical trial data, with R&D expenses already priced in.

Ekuitas saben Saham cuebiopharma.com (CUE): kanggo periode 04.07.2022 - 28.10.2026

cuebiopharma.com - rincian analitis lan metrik utama (CUE)

- rega lan prakiraan konsensus rega:

Rega saham Cue Biopharma, Inc.|CUE - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Nilai pasar Cue Biopharma, Inc.|CUE - Total Nilai Perusahaan

- data kapitalisasi buku:

Aset Bersih saben Siji Saham Cue Biopharma|CUE - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku cuebiopharma.com|CUE - Gunggung Aset Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas Cue Biopharma, Inc.|CUE - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Cue Biopharma|CUE - Utang perusahaan|Rasio utang marang kapitalisasi buku Cue Biopharma, Inc.

Pambiji fundamental perusahaan:Cue Biopharma, Inc., CUE

Cue Biopharma, Inc. (CUE) develops innovative cancer drugs within a protected US macro environment where geopolitical risks are minimal. This specific context is reflected in the calculation of net equity per share, which allows for an assessment of the issuer's real asset value and its solvency by analyzing book value per share to determine long-term growth potential.

Pesaing Cue Biopharma, Inc. (CUE)